P Dunn1, D Webb2, T P Olenginski2. 1. Geisinger Medical Center, 100 N Academy Ave, Danville, PA, 17822, USA. pdunn1@geisinger.edu. 2. Geisinger Medical Center, 100 N Academy Ave, Danville, PA, 17822, USA.
Abstract
Geisinger Health System (GHS) high-risk osteoporosis clinic (HiROC), which treats patients with low-trauma, fragility fractures, reports their 2013-2015 performance measures in secondary fracture prevention. This fracture liaison service (FLS) pathway treats 75% of high-risk, drug eligible patients, compared to 13.8% in GHS primary care. This performance points to the need for more FLS programs throughout the world. INTRODUCTION: The purpose of this study is to analyze and report ongoing performance measures in outpatient and inpatient high-risk osteoporosis clinic (HiROC) program designed for patients with low-trauma, fragility fractures. METHODS: Retrospective chart review of outpatient HiROC (511 patients) and inpatient HiROC (1279 patients) performance from 2013 to 2015 is reported within Geisinger Health System (GHS). RESULTS: Similar to a prior report, we document that Geisinger's branded outpatient and inpatient HiROC pathways continue to function as an all-fracture FLS. Importantly, this analysis emphasizes the importance of FLS care that HiROC's treatment rate of 75% was markedly superior to GHS-PCP care of 13.8%. However, a large percentage of patients (37.8%) were lost to follow-up care. This led to the identification of multiple care gaps/barriers to ideal best practice. CONCLUSIONS: FLS programs use case finding strategies and address secondary fracture prevention. GHS HiROC's performance and initiation of drug therapy in this fracture patient population contrasts with GHS-PCP care's much lower rate of treatment, documenting the need for ongoing FLS care. Importantly, the results of this analysis have prompted the beginnings of GHS programmatic changes, designed to narrow the reported care gaps in this mature FLS.
Geisinger Health System (GHS) high-risk osteoporosis clinic (HiROC), which treats patients with low-trauma, fragility fractures, reports their 2013-2015 performance measures in secondary fracture prevention. This fracture liaison service (FLS) pathway treats 75% of high-risk, drug eligible patients, compared to 13.8% in GHS primary care. This performance points to the need for more FLS programs throughout the world. INTRODUCTION: The purpose of this study is to analyze and report ongoing performance measures in outpatient and inpatient high-risk osteoporosis clinic (HiROC) program designed for patients with low-trauma, fragility fractures. METHODS: Retrospective chart review of outpatient HiROC (511 patients) and inpatient HiROC (1279 patients) performance from 2013 to 2015 is reported within Geisinger Health System (GHS). RESULTS: Similar to a prior report, we document that Geisinger's branded outpatient and inpatient HiROC pathways continue to function as an all-fracture FLS. Importantly, this analysis emphasizes the importance of FLS care that HiROC's treatment rate of 75% was markedly superior to GHS-PCP care of 13.8%. However, a large percentage of patients (37.8%) were lost to follow-up care. This led to the identification of multiple care gaps/barriers to ideal best practice. CONCLUSIONS: FLS programs use case finding strategies and address secondary fracture prevention. GHS HiROC's performance and initiation of drug therapy in this fracture patient population contrasts with GHS-PCP care's much lower rate of treatment, documenting the need for ongoing FLS care. Importantly, the results of this analysis have prompted the beginnings of GHS programmatic changes, designed to narrow the reported care gaps in this mature FLS.
Entities:
Keywords:
Care gaps; FLS; HiROC; Osteoporosis; Quality improvement
Authors: T P Olenginski; G Maloney-Saxon; C K Matzko; K Mackiewicz; H L Kirchner; A Bengier; E D Newman Journal: Osteoporos Int Date: 2014-11-15 Impact factor: 4.507
Authors: Jennifer M Grossman; Rebecca Gordon; Veena K Ranganath; Chad Deal; Liron Caplan; Weiling Chen; Jeffrey R Curtis; Daniel E Furst; Maureen McMahon; Nivedita M Patkar; Elizabeth Volkmann; Kenneth G Saag Journal: Arthritis Care Res (Hoboken) Date: 2010-07-26 Impact factor: 4.794
Authors: Brian Oppermann; William Ayoub; Eric Newman; G Craig Wood; Thomas P Olenginski Journal: J Clin Densitom Date: 2010 Jul-Sep Impact factor: 2.617
Authors: Lenore Buckley; Gordon Guyatt; Howard A Fink; Michael Cannon; Jennifer Grossman; Karen E Hansen; Mary Beth Humphrey; Nancy E Lane; Marina Magrey; Marc Miller; Lake Morrison; Madhumathi Rao; Angela Byun Robinson; Sumona Saha; Susan Wolver; Raveendhara R Bannuru; Elizaveta Vaysbrot; Mikala Osani; Marat Turgunbaev; Amy S Miller; Timothy McAlindon Journal: Arthritis Rheumatol Date: 2017-06-06 Impact factor: 10.995
Authors: M K Javaid; A Sami; W Lems; P Mitchell; T Thomas; A Singer; R Speerin; M Fujita; D D Pierroz; K Akesson; P Halbout; S Ferrari; C Cooper Journal: Osteoporos Int Date: 2020-04-08 Impact factor: 4.507